Neurocrine Biosciences Inc

2026-08-13 20:02; UTC

Neurocrine Biosciences shares decline as Morgan Stanley lowers price target to $182, citing safety concerns over VYKAT XR and reports of serious adverse events.

2026-08-12 21:11; UTC

Neurocrine Biosciences published positive KINECT-PRO™ study results, yet shares are lower in after-market hours, continuing a trend of declining daily closes.

2026-08-10 19:36; UTC

Neurocrine Biosciences initiates a Phase 1 study for NBIP-'1968, contributing to a rise in shares during the session. The stock remains below its 20-day moving average.

2026-08-07 19:46; UTC

Neurocrine Biosciences initiates a Phase 1 study for NBIP-'1968, a GLP-1/GIP/glucagon receptor triple agonist for obesity, boosting shares during Friday's session.

2026-08-06 19:36; UTC

Neurocrine Biosciences Inc shares are lower during Thursday's session, continuing a decline since Wednesday's close, with no specific news identified.

2026-08-05 23:46; UTC

Neurocrine Biosciences Inc shares are higher in after-market trading, buoyed by investor interest despite disappointing private sector employment data.

2026-08-04 19:26; UTC

Wedbush raised its price target on Neurocrine Biosciences to $194, while Canaccord Genuity increased its target to $210. Shares are trading roughly flat.

2026-08-03 20:51; UTC

Neurocrine Biosciences Inc shares are higher in after-market trading, reflecting a positive trend in the biotechnology sector amid broader market gains.

2026-07-31 23:56; UTC

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

2026-07-30 21:51; UTC

Neurocrine Biosciences reported second-quarter revenues of $959 million and raised 2026 INGREZZA sales guidance, with shares trading higher in after-market hours.

2026-07-29 18:46; UTC

Neurocrine Biosciences Inc shares are trading lower today with no specific news identified. The stock fluctuated earlier in the session amid broader market activity.

2026-07-28 23:41; UTC

Neurocrine Biosciences Inc shares are higher in after-market hours, rebounding from an earlier dip and maintaining a position above the 20-day moving average.

2026-07-27 19:21; UTC

Neurocrine Biosciences shares are higher as Cantor Schimmer ranks it among top picks, citing undervaluation and expected advancements in its portfolio.

2026-07-24 20:07; UTC

Neurocrine Biosciences Inc shares are higher today, despite an earlier pullback. Broader market sentiment is influenced by falling oil prices easing inflation concerns.

2026-07-22 19:51; UTC

Neurocrine Biosciences Inc. appointed Samir Siddhanti as Chief Business Officer. Despite this leadership change, shares are trading lower amid cautious investor sentiment.

2026-07-21 19:51; UTC

Neurocrine shares rise after Guggenheim raises price target to $200.

2026-07-20 23:46; UTC

Neurocrine Biosciences Inc is trading higher in after-market hours, maintaining a strong performance above its 20-day moving average and near its one-month range.